The Innovator IBD® 50 ETF (FFTY), a passively managed fund with a concentrated portfolio and ultrahigh turnover, is significantly outperforming benchmarks like IVV and QQQ in 2025. However, this recent strong performance is viewed skeptically due to its historical underperformance; from 2015-2025, its annualized return was nearly three times lower than IVV's, capturing 154% of its downside. Concerns about sustainable outperformance are further compounded by its 1,304% turnover, relatively small AUM, and a high 0.80% expense ratio.
The Innovator IBD® 50 ETF (FFTY) is currently exhibiting significant outperformance against benchmarks like IVV and QQQ in 2025. However, this recent strength is juxtaposed against a history of underperformance, with FFTY's annualized return from May 2015 to September 2025 being almost three times lower than IVV's. This suggests that the current strong showing may be an anomaly rather than a sustainable trend. The ETF's structural characteristics present notable concerns for long-term investors. It operates with an ultrahigh turnover rate of 1,304%, indicating frequent portfolio rebalancing that can incur significant trading costs. Furthermore, its relatively small Assets Under Management (AUM) and a high net expense ratio of 0.80% further detract from potential net returns. Historically, FFTY has demonstrated poor downside protection, capturing nearly 154% of the market's downturns. This high downside capture, combined with the fund's concentrated portfolio and high expense structure, raises questions about the sustainability of its current outperformance. The analyst's cautious tone reflects skepticism regarding its ability to maintain its 2025 momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.50
Ticker Sentiment
